Accelerate Your MTAP Deletion Drug Discovery with Clinically Relevant In Vivo Models
Methylthioadenosine phosphorylase (MTAP) deficiency, also known as MTAP deletion, occurs frequently in solid tumors, including pancreatic cancer and non-small cell lung cancer (NSCLC). Tumors with MTAP deletion are generally more aggressive and associated with shorter overall survival compared to those with intact MTAP.
How Our Unique Screen Can Help:
-
Clinically Relevant ModelsLow passage MTAP-deficient PDX models preserving the heterogeneous genetic background of cancer patients.
-
Manually curated CDKN2A statusAll MTAP-deficient PDXs harbor partial of complete CDKN2A gene deletion, and a variety of activated oncogenic drivers and tumor suppressor pathways alterations.
-
Translational Multi-omicsMatched clinical histories, WES, RNAseq, proteomics, and biomarker data available through Lumin for deeper insights.
-
Synthetic-lethalityIdeal models to test compounds or therapeutic strategies that target metabolic vulnerabilities that arise because of loss of methionine salvage and nucleotide metabolism in MTAP-null tumors.
-
Exploring MTAP-null backgroundGreat opportunity to evaluate the efficacy of treatments directed against oncogenic drivers and targets a MTAP-null human background.
-
Mechanism of Action ClarityEnables clean readouts of pathway modulation, vulnerability, and resistance mechanisms across diverse solid tumors.
MTAP Deletion In Vivo Screen
Our screen includes 44 models from tumors with an MTAP deletion.
|
Model
|
Control/Test model
|
Tumor type
|
SoC for Screen
|
|---|---|---|---|
|
CTG-0492
|
Control
|
Pancreatic
|
TBD - this is a MTAP wt model and serves as a control; SoC determined by the choice of the treatment on the MTAP mut model
|
|
CTG-1328
|
Control
|
Pancreatic
|
TBD - this is a MTAP wt model and serves as a control; SoC determined by the choice of the treatment on the MTAP mut model
|
|
CTG-1363
|
Control
|
NSCLC
|
TBD - this is a MTAP wt model and serves as a control; SoC determined by the choice of the treatment on the MTAP mut model
|
|
CTG-3651
|
Control
|
NSCLC
|
TBD - this is a MTAP wt model and serves as a control; SoC determined by the choice of the treatment on the MTAP mut model
|
|
CTG-0838
|
Control
|
NSCLC
|
TBD - this is a MTAP wt model and serves as a control; SoC determined by the choice of the treatment on the MTAP mut model
|
|
CTG-1353
|
Control
|
NSCLC
|
TBD - this is a MTAP wt model and serves as a control; SoC determined by the choice of the treatment on the MTAP mut model
|
|
CTG-2535
|
Control
|
NSCLC
|
TBD - this is a MTAP wt model and serves as a control; SoC determined by the choice of the treatment on the MTAP mut model
|
|
CTG-2539
|
Control
|
NSCLC
|
TBD - this is a MTAP wt model and serves as a control; SoC determined by the choice of the treatment on the MTAP mut model
|
|
CTG-3236
|
Control
|
NSCLC
|
TBD - this is a MTAP wt model and serves as a control; SoC determined by the choice of the treatment on the MTAP mut model
|
|
CTG-3855
|
Control
|
NSCLC
|
TBD - this is a MTAP wt model and serves as a control; SoC determined by the choice of the treatment on the MTAP mut model
|
|
CTG-0288
|
Test
|
Pancreatic
|
Daraxonrasib; Capivasertib; Ipatasertib
|
|
CTG-0178
|
Test
|
NSCLC
|
Sapanisertib; Everolimus
|
|
CTG-0286
|
Test
|
Pancreatic
|
Daraxonrasib; Osimertinib
|
|
CTG-0289
|
Test
|
Pancreatic
|
Datopotamab
|
|
CTG-0290
|
Test
|
Pancreatic
|
Daraxonrasib; Datopotamab
|
|
CTG-0300
|
Test
|
Pancreatic
|
Daraxonrasib; Datopotamab; Ulixertib
|
|
CTG-0305
|
Test
|
Pancreatic
|
Datopotamab; Olaparib
|
|
CTG-0307
|
Test
|
Pancreatic
|
Daraxonrasib; Datopotamab; Ulixertib
|
|
CTG-0309
|
Test
|
Pancreatic
|
Daraxonrasib; Datopotamab
|
|
CTG-0743
|
Test
|
NSCLC
|
Daraxonrasib; Telisotuzumab
|
|
CTG-0842
|
Test
|
Pancreatic
|
Daraxonrasib; Erlotinib; Ulixertib
|
|
CTG-0955
|
Test
|
Pancreatic
|
Daraxorasib; Osimertinib
|
|
CTG-0961
|
Test
|
Pancreatic
|
Daraxonrasib; Erlotinib; Ulixertib
|
|
CTG-1194
|
Test
|
NSCLC
|
Abemaciclib; Palbociclib
|
|
CTG-1217
|
Test
|
NSCLC
|
Datopotamab
|
|
CTG-1275
|
Test
|
NSCLC
|
Datopotamab; Alpelisib; Abemaciclib; Palbociclib; Erlotinib; Osimertinib
|
|
CTG-1331
|
Test
|
Pancreatic
|
Ulixertib; Palbociclib; Abemaciclib
|
|
CTG-1347
|
Test
|
Pancreatic
|
Daraxonrasib; Datopotamab; Ulixertib
|
|
CTG-1372
|
Test
|
NSCLC
|
Sapanisertib; Everolimus; Alpelisib; Palbociclib
|
|
CTG-1643
|
Test
|
Pancreatic
|
Olaparib; Daraxonrasib
|
|
CTG-1932
|
Test
|
NSCLC
|
Zoldonrasib
|
|
CTG-2205
|
Test
|
Pancreatic
|
Daraxonrasib; Alpelisib; Ulixertib; Palbociclib
|
|
CTG-2536
|
Test
|
NSCLC
|
Trastuzumab deruxtecan; Tucatinib
|
|
CTG-2548
|
Test
|
NSCLC
|
Datopotamab; Erlotinib
|
|
CTG-2555
|
Test
|
NSCLC
|
Alpelisib; Datopotamab
|
|
CTG-2669
|
Test
|
NSCLC
|
Capmatinib, Tepotinib, Erlotinib
|
|
CTG-2776
|
Test
|
NSCLC
|
Sapanisertib; Everolimus
|
|
CTG-2803
|
Test
|
NSCLC
|
Amivantamab; Sorafenib; Sunitinib; Pazopanib
|
|
CTG-3348
|
Test
|
Pancreatic
|
Datopotamab; Sotorasib
|
|
CTG-3377
|
Test
|
NSCLC
|
Alpelisib; Datopotamab; Pembrolizumab
|
|
CTG-3574
|
Test
|
NSCLC
|
Sotorasib; Adagrasib; Sapanisertib; Everolimus
|
|
CTG-3710
|
Test
|
NSCLC
|
Pralsetinib, Selpercatinib
|
|
CTG-4001
|
Test
|
NSCLC
|
Osimertinib
|
|
CTG-4267
|
Test
|
NSCLC
|
Osimertinib
|